human
metapneumoviru
hmpv
infect
children
five
year
age
viru
caus
upper
lower
respiratori
tract
diseas
life
threaten
highrisk
popul
includ
young
children
expos
viru
first
time
elderli
current
standard
treatment
licens
vaccin
hmpv
although
sever
attract
vaccin
candid
develop
preclin
studi
rais
awar
impact
hmpv
public
health
need
drive
research
complet
vaccin
develop
therebi
prevent
signific
virusassoci
morbid
mortal
worldwid
human
metapneumoviru
hmpv
negativestrand
rna
viru
replic
cytoplasm
hmpv
avian
metapneumoviru
ampv
closest
known
rel
hmpv
member
genu
metapneumoviru
famili
pneumovirida
hmpv
share
mani
featur
respiratori
syncyti
viru
rsv
genu
orthopneumoviru
famili
pneumovirida
hmpv
genom
approxim
nucleotid
length
hmpv
virion
contain
ribonucleocapsid
core
consist
viral
rna
vrna
nucleocapsid
n
protein
polymeras
l
protein
phosphoprotein
p
protein
matrix
protein
line
inner
face
virion
envelop
envelop
spike
project
viru
includ
small
hydrophob
sh
protein
attach
g
fusion
f
glycoprotein
protein
regul
rna
synthesi
support
viru
growth
hamster
model
hmpv
exist
filament
spheric
particl
diamet
rang
nm
appear
morpholog
similar
rsv
member
famili
paramyxovirida
fact
hmpv
rsv
previous
classifi
member
paramyxovirida
famili
list
recent
chang
intern
committe
taxonomi
virus
ictv
hmpv
envelop
glycoprotein
includ
g
f
protein
open
read
frame
orf
g
encod
residu
glycoprotein
unrel
nucleotid
amino
acid
sequenc
pneumoviru
paramyxoviru
g
protein
g
protein
bind
heparan
sulfat
glycosaminoglycan
found
airway
epitheli
cell
nasal
lung
tissu
initi
viral
entri
orf
f
encod
residu
glycoprotein
share
amino
acid
ident
pneumoviru
f
protein
ident
paramyxoviru
f
protein
case
pneumovirus
paramyxovirus
f
protein
synthes
precursor
protein
subsequ
cleav
fusioncap
subunit
form
larg
trimer
mushroomlik
extracellular
head
addit
ctermin
transmembran
tm
cytoplasm
tail
region
highresolut
structur
obtain
hmpv
f
protein
ectodomain
prefus
postfus
form
structur
share
mani
structur
featur
common
prefus
postfus
form
f
protein
rsv
paramyxovirus
receptor
bind
f
protein
undergo
dramat
chang
structur
caus
membran
fusion
allow
viru
entri
strain
hmpv
catalyz
membran
fusion
neutral
ph
other
trigger
low
ph
endosom
addit
membran
fusion
f
protein
also
facilit
receptor
bind
argglyasp
rgd
motif
bind
integrin
hmpv
discov
isol
dozen
young
children
netherland
soon
initi
identif
hmpv
found
global
etiolog
agent
respiratori
infect
young
children
elderli
adult
temper
climat
hmpv
epidem
tend
occur
winter
spring
tropic
climat
sporad
polymeras
chain
reaction
pcr
assay
immunofluoresc
assay
often
use
diagnos
hmpv
assay
score
viral
nucleic
acid
protein
acut
infect
may
also
score
residu
viral
compon
replicationcompet
viru
clear
serum
antivir
antibodi
serv
anoth
marker
hmpv
exposur
b
cell
respons
hmpv
rapid
longlast
serolog
find
suggest
hmpv
circul
global
human
decad
first
discoveri
children
first
infect
hmpv
age
five
nearli
teenag
adult
seroposit
late
discoveri
hmpv
like
due
viru
slow
replic
requir
trypsin
minim
cytopath
effect
cpe
mani
tissu
cultur
cell
line
hmpv
diseas
often
attribut
anoth
viru
rsv
influenza
tertiari
monkey
kidney
epitheli
cell
eventu
found
support
robust
hmpv
amplif
cpe
follow
hmpv
exposur
innat
cell
b
cell
cell
immun
respons
usual
develop
within
day
assist
rapid
viru
clearanc
howev
hmpv
caus
upper
respiratori
tract
urt
lower
respiratori
tract
lrt
diseas
case
exacerb
immun
function
lrt
diseas
sever
particularli
individu
expos
viru
first
time
outcom
includ
bronchiol
pneumonia
result
death
among
numer
studi
hospit
outpati
children
worldwid
hmpv
associ
respiratori
ill
studi
edward
et
al
unit
state
estim
hmpv
respons
annual
hospit
rate
approxim
per
children
age
five
studi
davi
et
al
unit
state
hospit
highest
children
age
year
approxim
per
person
year
hospit
children
underli
complex
chronic
condit
pulmonari
disord
requir
intens
care
requir
mechan
ventil
recent
studi
norway
describ
moe
et
al
children
hospit
lrt
diseas
diagnos
hmpv
studi
sever
symptom
observ
among
children
age
year
indic
matern
antibodi
provid
degre
protect
infant
risk
factor
seriou
diseas
includ
histori
prematur
birth
chronic
airway
diseas
histori
prematur
birth
similarli
identifi
risk
factor
sever
hmpv
diseas
pancham
et
al
studi
preschool
children
reinfect
hmpv
common
albeit
usual
mild
viru
threat
increas
human
immun
system
weaken
context
hematopoiet
stem
cell
transplant
age
individu
compris
anoth
vulner
popul
due
wane
immun
function
standard
treatment
hmpv
except
support
care
ribavirin
nucleosid
analogu
exhibit
antihmpv
activ
laboratori
studi
use
clinic
studi
yield
conflict
result
efficaci
rout
administr
dose
ribavirin
treatment
respiratori
infect
topic
continu
debat
therapi
develop
block
hmpv
fusion
exampl
peptid
deriv
heptad
repeat
domain
hmpv
f
protein
shown
significantli
reduc
viral
load
anim
studi
addit
small
interf
rna
use
block
hmpv
infect
intraven
immun
globulin
ivig
hmpvspecif
monoclon
antibodi
could
potenti
use
neutral
hmpv
benefit
treatment
option
hmpv
diseas
proven
rsv
virusspecif
antibodi
success
prophylax
particularli
vulner
children
includ
prematur
infant
infant
heartlung
diseas
treatment
increas
number
treatment
option
method
develop
expedit
screen
antihmpv
drug
candid
ongo
studi
hmpv
protein
structurefunct
also
assist
futur
drug
vaccin
develop
vaccin
effect
method
control
infecti
diseas
immun
system
prime
viru
exposur
elimin
viru
urt
avoid
traffick
viru
lung
greatest
damag
caus
sever
hmpv
vaccin
produc
test
preclin
studi
includ
recombin
vaccin
vaccin
base
alpha
viru
bovin
kill
viru
test
although
concern
kill
viru
may
exacerb
diseas
case
formalininactiv
rsv
vaccin
clinic
test
protein
peptid
viru
like
particl
vlp
vaccin
also
tri
liveattenu
hmpv
vaccin
produc
includ
coldadapt
variant
virus
mutat
f
polymeras
protein
hmpv
surfac
glycoprotein
g
f
test
vaccin
antigen
f
g
gene
individu
express
recombin
human
parainfluenza
virustyp
construct
test
hamster
f
construct
exhibit
better
immunogen
separ
studi
solubl
g
protein
express
ectodomain
without
transmembran
domain
cytoplasm
tail
elicit
neutral
antibodi
protect
challeng
cotton
rat
contrast
hmpv
f
vaccin
produc
use
varieti
differ
vector
system
repeatedli
gener
protect
immun
respons
preclin
anim
model
sendai
viru
sev
recent
test
candid
vector
hmpv
f
vaccin
sev
mous
parainfluenza
viru
close
relat
recombin
produc
insert
hmpv
f
gene
sev
backbon
f
hn
gene
vaccin
deliv
intranas
small
research
anim
induc
robust
immun
respons
protect
hmpv
challeng
hmpv
vaccin
rare
progress
clinic
studi
although
liveattenu
vaccin
test
adult
new
vaccin
program
numer
step
requir
advanc
vaccin
concept
clinic
applic
step
typic
includ
limit
vaccin
design
ii
preclin
vaccin
test
immunogen
efficaci
small
andor
larg
anim
model
iii
prepar
pilot
vaccin
lot
iv
stabil
test
v
toxicolog
test
vi
applic
institut
govern
regulatori
board
approv
vaccin
produc
good
manufactur
practic
gmp
associ
clinic
protocol
vii
clinic
test
vaccin
phase
ii
iii
regulatori
oversight
viii
licens
applic
approv
ix
vaccin
distribut
target
popul
use
appropri
transport
storag
condit
x
public
accept
vaccin
use
xi
continu
vaccin
monitor
safeti
efficaci
lag
develop
hmpv
vaccin
may
due
least
part
priorit
respiratori
viru
vaccin
program
eg
influenza
viru
rsv
coronaviru
threat
hmpv
infect
diseas
continu
unab
perhap
fulli
recogn
respiratori
viral
infect
occur
often
assum
due
influenza
viru
infect
term
flu
diagnost
may
avail
score
influenza
viru
possibl
rsv
hmpv
new
multiplex
assay
includ
hmpv
cost
prohibit
mani
hospit
therefor
diseas
caus
hmpv
go
undiagnos
unreport
recommend
effort
increas
hmpv
field
advanc
research
effort
reveal
mechan
viru
induc
host
immun
respons
improv
surveil
measur
burden
hmpv
diseas
improv
hmpv
awar
among
clinician
patient
develop
lowcost
diagnost
assay
hmpv
develop
new
drug
treatment
option
hmpv
advanc
hmpv
vaccin
clinic
trial
licensur
dedic
new
fund
effort
conduct
vaccin
clinic
trial
might
provid
greatest
benefit
hmpv
field
escort
vaccin
candid
beyond
stage
preclin
test
licens
efficaci
vaccin
hmpv
could
prevent
substanti
number
hospit
among
children
adult
worldwid
human
metapneumoviru
hmpv
respiratori
syncyti
viru
rsv
parainfluenza
viru
type
sendai
viru
sev
cytopath
effect
cpe
fusion
protein
f
attach
glycoprotein
g
good
manufactur
practic
gmp
